

(51) International Patent Classification:
A23L 1/30 (2006.01)(21) International Application Number:
PCT/IB2012/050511(22) International Filing Date:
3 February 2012 (03.02.2012)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/441,451 10 February 2011 (10.02.2011) US(71) Applicant (for all designated States except US): **WYETH LLC** [US/US]; Five Giralda Farms, Madison, NJ 07940 (US).

(72) Inventor; and

(75) Inventor/Applicant (for US only): **FRANTZ, David, Curtis** [US/US]; Pfizer Global Research and Development, 500 Arcola Road, Collegeville, PA 19426 (US).(74) Agents: **POKRAS, Bruce, A.** et al.; Pfizer Inc., Five Giralda Farms, Madison, NJ 07940 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,

HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

- as to the identity of the inventor (Rule 4.17(i))
- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- without international search report and to be republished upon receipt of that report (Rule 48.2(g))

(54) Title: MODULATION OF GROWTH OF BIFIDOBACTERIA USING A COMBINATION OF OLIGOSACCHARIDES FOUND IN HUMAN MILK

FIG. 1: 2'-Fucosyllactose Growth Curve Assay – *Bifidobacterium bifidum*(57) Abstract: A prebiotic formulation for oral administration to a human comprising 2'-fucosyllactose, 3'-sialyllactose and 6'-sialyllactose, and a method for modulating or stimulating the growth of *Bifidobacteria* in the gut. The formulation may be an infant formula.